[go: up one dir, main page]

MA53665B1 - Agonistes du récepteur farnésoïde x et leurs utilisations - Google Patents

Agonistes du récepteur farnésoïde x et leurs utilisations

Info

Publication number
MA53665B1
MA53665B1 MA53665A MA53665A MA53665B1 MA 53665 B1 MA53665 B1 MA 53665B1 MA 53665 A MA53665 A MA 53665A MA 53665 A MA53665 A MA 53665A MA 53665 B1 MA53665 B1 MA 53665B1
Authority
MA
Morocco
Prior art keywords
farnesoid
receptor agonists
compounds
methods
receptor
Prior art date
Application number
MA53665A
Other languages
English (en)
Other versions
MA53665A (fr
Inventor
Nicholas D. Smith
Steven P. Govek
Karensa L. Douglas
Andiliy G. Lai
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of MA53665A publication Critical patent/MA53665A/fr
Publication of MA53665B1 publication Critical patent/MA53665B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biotechnology (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés qui sont des agonistes du récepteur farnésoïde X, des procédés de fabrication de tels composés, des compositions pharmaceutiques et des médicaments comprenant de tels composés, et des méthodes d'utilisation de tels composés dans le traitement d'états, de maladies ou de troubles associés à l'activité du récepteur farnésoïde X.
MA53665A 2018-09-18 2019-09-17 Agonistes du récepteur farnésoïde x et leurs utilisations MA53665B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862733004P 2018-09-18 2018-09-18
US201862733006P 2018-09-18 2018-09-18
US201962881560P 2019-08-01 2019-08-01
EP19862391.0A EP3852748B1 (fr) 2018-09-18 2019-09-17 Agonistes du récepteur farnésoïde x et leurs utilisations
PCT/US2019/051603 WO2020061113A1 (fr) 2018-09-18 2019-09-17 Agonistes du récepteur farnésoïde x et leurs utilisations

Publications (2)

Publication Number Publication Date
MA53665A MA53665A (fr) 2021-07-28
MA53665B1 true MA53665B1 (fr) 2025-09-30

Family

ID=69887982

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53665A MA53665B1 (fr) 2018-09-18 2019-09-17 Agonistes du récepteur farnésoïde x et leurs utilisations

Country Status (20)

Country Link
US (4) US11084817B2 (fr)
EP (2) EP4596543A3 (fr)
JP (1) JP7554739B2 (fr)
KR (2) KR102810978B1 (fr)
CN (1) CN113056271B (fr)
AU (2) AU2019344903B2 (fr)
BR (1) BR112021004919A2 (fr)
CA (1) CA3112411A1 (fr)
CL (1) CL2021000632A1 (fr)
DK (1) DK3852748T3 (fr)
FI (1) FI3852748T3 (fr)
IL (1) IL281475B2 (fr)
LT (1) LT3852748T (fr)
MA (1) MA53665B1 (fr)
MX (1) MX2021003110A (fr)
PH (1) PH12021550605A1 (fr)
PT (1) PT3852748T (fr)
SG (1) SG11202102651SA (fr)
TW (1) TWI833805B (fr)
WO (1) WO2020061113A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170182A1 (fr) * 2017-03-15 2018-09-20 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
IL269068B (en) 2017-03-15 2022-09-01 Metacrine Inc Paranoid x receptor agonists and uses thereof
WO2020061113A1 (fr) 2018-09-18 2020-03-26 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
IL293892A (en) 2020-01-15 2022-08-01 Inserm Institut National De La Sant? Et De La Rech M?Dicale Use of fxr agonists for treating an infection by hepatitis d virus
IL296539A (en) * 2020-03-18 2022-11-01 Metacrine Inc Farnesoid x receptor agonists for the treatment of disease
EP4121012A1 (fr) * 2020-03-18 2023-01-25 Metacrine, Inc. Formulations d'un agoniste du récepteur farnésoïde x
BR112022018596A2 (pt) * 2020-03-18 2023-03-07 Metacrine Inc Formas cristalinas de um agonista de receptor farnesoide x
US20240100125A1 (en) 2021-01-14 2024-03-28 Enyo Pharma Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
WO2022229302A1 (fr) 2021-04-28 2022-11-03 Enyo Pharma Potentialisation forte d'effets d'agonistes de tlr3 à l'aide d'agonistes de fxr en tant que traitement combiné
CN116554121A (zh) * 2023-05-05 2023-08-08 济南悟通生物科技有限公司 一种2-异丁基噻唑的合成方法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20013767A3 (cs) 1999-05-17 2002-04-17 Novo Nordisk A/S Sloučenina, farmaceutický prostředek, pouľití sloučeniny a způsob léčení
US6645980B1 (en) 2000-05-25 2003-11-11 Sepracor Inc. Heterocyclic analgesic compounds and methods of use thereof
CA2372887A1 (fr) 1999-05-25 2000-11-30 Sepracor Inc. Composes heterocycliques analgesiques et procedes d'utilisation de ces derniers
US6511980B2 (en) 2000-05-05 2003-01-28 Ortho Mcneil Pharmaceutical, Inc. Substituted diamine derivatives useful as motilin antagonists
JP2004509866A (ja) 2000-09-25 2004-04-02 アクテリオン　ファマシューティカルズ　リミテッド 置換アミノ−アザ−シクロアルカン
FR2815032B1 (fr) 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
FR2825706B1 (fr) 2001-06-06 2003-12-12 Pf Medicament Nouveaux derives de benzothienyle ou d'indole, leur preparation et leur utilisation comme inhibiteurs de proteines prenyl transferase
FR2839974B1 (fr) 2002-05-24 2004-07-16 Pf Medicament Derives de phenyl-furane ou de phenyl-thiophene,leur preparation et leur application a titre de medicament
WO2004009549A2 (fr) 2002-07-18 2004-01-29 Actelion Pharmaceuticals Ltd Piperidines utiles pour traiter des maladies du systeme nerveux central
BR0314126A (pt) 2002-09-20 2005-06-28 Pfizer Prod Inc Ligandos de amida acìclica e sulfonamida para o receptor de estrogênio
AU2003290796A1 (en) 2002-11-14 2004-06-15 The Scripps Research Institute Non-steroidal fxr agonists
US20050143449A1 (en) 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
AU2003298654A1 (en) 2002-11-15 2004-06-15 The Salk Institute For Biological Studies Structure of the farnesoid x receptor ligand binding domain and methods of use therefor
GB0309781D0 (en) 2003-04-29 2003-06-04 Glaxo Group Ltd Compounds
US7759348B2 (en) 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US7335658B2 (en) 2003-07-30 2008-02-26 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US7754711B2 (en) 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
WO2005058822A1 (fr) 2003-12-17 2005-06-30 Actelion Pharmaceuticals Ltd Cycloalcanes amines substitues
WO2005097760A1 (fr) 2004-03-26 2005-10-20 Rigel Pharmaceuticals, Inc. Composes antiviraux heterocycliques comportant des groupes fonctionnels metabolisables et leurs utilisations
WO2005113522A1 (fr) 2004-05-07 2005-12-01 Janssen Pharmaceutica, N.V. Inhibiteurs carboxamides d'azole de systèmes bactériens de sécrétion de protéine de type iii
JP2006199656A (ja) 2005-01-24 2006-08-03 Kowa Co アミド基を有する環状アミン化合物
MY144229A (en) 2006-01-26 2011-08-15 Xenon Pharmaceuticals Inc Pyridazine derivatives and their use as therapeutic agents
AU2007229637A1 (en) 2006-03-28 2007-10-04 Novartis Ag Amide derivatives and their application for the treatment of G protein related diseases
US20080081824A1 (en) 2006-09-29 2008-04-03 Bristol-Myers Squibb Company Substituted piperidines as modulators of chemokine receptor activity
WO2008065500A2 (fr) 2006-11-30 2008-06-05 Pfizer Products Inc. Hétéroaryl amides comme inhibiteurs du transport de la glycine de type i
NZ585370A (en) 2007-12-19 2012-09-28 Boehringer Ingelheim Int Viral polymerase inhibitors
WO2010001869A1 (fr) 2008-06-30 2010-01-07 武田薬品工業株式会社 Composé de benzène tétrasubstitué et son utilisation
JP2010077109A (ja) 2008-08-28 2010-04-08 Takeda Chem Ind Ltd 複素環化合物およびその用途
WO2011008915A1 (fr) 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridines inhibiteurs de kinases
JP2012532914A (ja) 2009-07-15 2012-12-20 メルク セローノ ソシエテ アノニム テトラゾール誘導体
FR2963005B1 (fr) 2010-07-23 2012-08-17 Sanofi Aventis Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique
EP3872076A1 (fr) 2011-03-23 2021-09-01 Trevena, Inc. Ligands de récepteurs opïoides, et leurs procédés d'utilisation et de production
EP2545964A1 (fr) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité
CN103648634B (zh) 2011-07-13 2016-05-18 M技术株式会社 控制了微晶粒径的微粒的制造方法
RU2543485C2 (ru) 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
GB201316824D0 (en) 2013-09-23 2013-11-06 R & D Vernalis Ltd New Chemical Entities
EP3116878A4 (fr) 2014-03-13 2018-02-14 Salk Institute for Biological Studies Agonistes fxr et leurs procédés de fabrication et d'utilisation
AU2015229055B2 (en) 2014-03-13 2019-09-12 Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
US20150258052A1 (en) 2014-03-13 2015-09-17 Salk Institute For Biological Studies Methods of using fexaramine and agents that increase sympathetic nervous system activity to promote browning of white adipose tissue
US10077268B2 (en) 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
US10301268B2 (en) 2014-03-13 2019-05-28 The Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
US20180116993A1 (en) 2015-01-22 2018-05-03 Xiamen University Modulators of farnesoid x receptor and methods for the use thereof
CA2979399A1 (fr) 2015-03-13 2016-09-22 Salk Institute For Biological Studies Traitement de diabetes auto-immuns latents des adultes a agonistes de recepteur x farnesoide pour activer les recepteurs intestinaux
WO2017018751A1 (fr) 2015-07-24 2017-02-02 동국대학교 산학협력단 Nouveau composé présentant une activité inhibitrice de blt et composition, destiné à prévenir ou à traiter des maladies inflammatoires, contenant ce dernier en tant que principe actif
WO2017049176A1 (fr) * 2015-09-16 2017-03-23 Metacrine, Inc. Agonistes du récepteur x farnésoïde et leurs utilisations
JP2018532772A (ja) 2015-09-16 2018-11-08 メタクリン，インク． ファルネソイドｘ受容体アゴニストおよびそれらの使用
AU2016323992B2 (en) 2015-09-16 2021-05-06 Eli Lilly And Company Farnesoid X receptor agonists and uses thereof
EP3350158A4 (fr) 2015-09-16 2019-05-08 Metacrine, Inc. Agonistes du récepteur x farnésoïde et leurs utilisations
CN105477636B (zh) * 2015-10-16 2019-09-17 厦门大学 使用阿维菌素及其衍生物治疗代谢疾病的方法
CN107126419B (zh) 2016-02-26 2020-06-19 石药集团中诺药业（石家庄）有限公司 一种奥贝胆酸片剂及其制备方法
WO2017170182A1 (fr) 2016-03-31 2017-10-05 株式会社Adeka Composition photosensible et nouveau composé
IL269068B (en) 2017-03-15 2022-09-01 Metacrine Inc Paranoid x receptor agonists and uses thereof
WO2018170182A1 (fr) 2017-03-15 2018-09-20 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
WO2018170167A1 (fr) 2017-03-15 2018-09-20 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
US20200131129A1 (en) 2017-03-15 2020-04-30 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
US20200131142A1 (en) 2017-03-15 2020-04-30 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
CZ2017298A3 (cs) 2017-05-26 2018-12-05 Zentiva, K.S. Amorfní formy obeticholové kyseliny
WO2020060007A1 (fr) 2018-09-17 2020-03-26 엘지전자 주식회사 Procédé et dispositif sans fil pour gérer une session de pdu dans une communication mobile 5g
WO2020061116A1 (fr) 2018-09-18 2020-03-26 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
CA3112414A1 (fr) 2018-09-18 2020-03-26 Metacrine, Inc. Agonistes du recepteur farnesoide x pour le traitement d'une maladie
WO2020061113A1 (fr) 2018-09-18 2020-03-26 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
WO2020061117A1 (fr) 2018-09-18 2020-03-26 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
WO2020061118A1 (fr) 2018-09-18 2020-03-26 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
BR112021004931A2 (pt) 2018-09-18 2021-06-01 Metacrine, Inc. formas cristalinas de um agonista de receptor farnesoide x
US20220054469A1 (en) 2018-09-18 2022-02-24 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
BR112022018596A2 (pt) 2020-03-18 2023-03-07 Metacrine Inc Formas cristalinas de um agonista de receptor farnesoide x
IL296539A (en) 2020-03-18 2022-11-01 Metacrine Inc Farnesoid x receptor agonists for the treatment of disease
EP4121012A1 (fr) 2020-03-18 2023-01-25 Metacrine, Inc. Formulations d'un agoniste du récepteur farnésoïde x

Also Published As

Publication number Publication date
IL281475A (en) 2021-04-29
AU2019344903A1 (en) 2021-05-13
US20210395253A1 (en) 2021-12-23
LT3852748T (lt) 2025-11-25
MA53665A (fr) 2021-07-28
KR20210076910A (ko) 2021-06-24
DK3852748T3 (da) 2025-10-06
EP3852748A1 (fr) 2021-07-28
US20200102308A1 (en) 2020-04-02
BR112021004919A2 (pt) 2021-06-01
CL2021000632A1 (es) 2021-07-23
EP4596543A2 (fr) 2025-08-06
WO2020061113A1 (fr) 2020-03-26
EP4596543A3 (fr) 2025-10-15
JP2022500392A (ja) 2022-01-04
CN113056271B (zh) 2024-10-29
SG11202102651SA (en) 2021-04-29
KR102810978B1 (ko) 2025-05-23
TWI833805B (zh) 2024-03-01
EP3852748B1 (fr) 2025-09-03
US20250289821A1 (en) 2025-09-18
JP7554739B2 (ja) 2024-09-20
US11773094B2 (en) 2023-10-03
CN113056271A (zh) 2021-06-29
EP3852748A4 (fr) 2022-05-18
AU2019344903B2 (en) 2025-02-27
PT3852748T (pt) 2025-10-24
US11084817B2 (en) 2021-08-10
CA3112411A1 (fr) 2020-03-26
IL281475B1 (en) 2024-12-01
FI3852748T3 (fi) 2025-10-22
KR20250073553A (ko) 2025-05-27
PH12021550605A1 (en) 2021-10-04
IL281475B2 (en) 2025-04-01
AU2025203804A1 (en) 2025-06-12
MX2021003110A (es) 2021-05-13
US20230382913A1 (en) 2023-11-30
TW202024052A (zh) 2020-07-01

Similar Documents

Publication Publication Date Title
MA53665B1 (fr) Agonistes du récepteur farnésoïde x et leurs utilisations
MA58049B1 (fr) Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) à pipéridine à double substitution gem et leurs utilisations
MA31764B1 (fr) Composés et compositions en tant que modulateurs de l'activité de gpr119
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA52288B1 (fr) Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
MA47392B1 (fr) Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques
MA30462B1 (fr) Composes de pyridylamide antagonistes des canaux calciques de type t
MA47043A1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
MA30339B1 (fr) Azolopyrimidines inhibitrices de l'activite du recepteur cannabinoïde 1
MA56019A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA40290A1 (fr) Agents immunorégulateurs
MA29931B1 (fr) Inhibiteurs de la proteine d'activation de la 5-lipoxygenase (flap)
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA28660B1 (fr) Composes et compositions en tant que modulateurs de ppar
MA46665B1 (fr) Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MA43113A (fr) Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
MA58646A1 (fr) Tubulysines et conjugués tubulysines-protéines
MA40875B1 (fr) 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
MA46611A (fr) Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs
WO2017177024A8 (fr) Méthodes de traitement de troubles oculaires
WO2019018451A3 (fr) Compositions et méthodes de prévention et de traitement d'effets de proximité induits par rayonnement provoqués par un rayonnement ou une radiothérapie